- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02094729
A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
June 4, 2015 updated by: Eisai Co., Ltd.
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamic response of repeated intravenous infusions of BAN2401 in subjects with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose study in a total of 24 subjects (8 subjects per cohort) with MCI due to AD and mild AD.
The study consists of three cohorts to evaluate the safety, tolerability and PK of BAN2401 at three dose levels (2.5, 5, and 10 mg/kg).
Each cohort consists of Screening Period before randomization, Treatment Period from randomization to last dose, and Follow-up Period after last dose.
Cohorts 1, 2, and 3 will receive 2.5 mg/kg, 5 mg/kg, and 10 mg/kg of BAN2401, respectively.
Study Type
Interventional
Enrollment (Actual)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Hyogo
-
Kobe, Hyogo, Japan
-
-
Miyagi
-
Sendai, Miyagi, Japan
-
-
Okayama
-
Kurashiki, Okayama, Japan
-
-
Tokyo
-
Koto-ku, Tokyo, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
MCI due to AD
- Subjects who have clinical and cognitive symptoms consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) core criteria for MCI
- Subjects who have a Clinical Dementia Rating (CDR) of 0.5 and a memory box score of 0.5 or greater at Screening
- Subjects who report a history of subjective memory decline with slow progression at least 1 year before Screening, or subjects whose information provider or attending physician reports a history of memory decline with slow progression at least 1 year before Screening
Subjects with objective impairment in episodic memory as indicated by 1-1.5 standard deviations below age-adjusted mean in the Wechsler Memory Scale-Revised (WMS-R) logical memory II (delayed recall) at Screening:
- less than or equal to 15 for age 50 to 64 years
- less than or equal to 12 for age 65 to 69 years
- less than or equal to 11 for age 70 to 74 years
- less than or equal to 9 for age 75 to 79 years
- less than or equal to 7 for age 80 to 90 years
Mild AD
- Subjects who meet the NIA-AA core clinical criteria for probable AD
Subjects who have a CDR of 0.5 or 1.0 and a memory box score of 0.5 or greater at Screening
All subjects
- Male or female subjects aged between 50 and 90 years, inclusive, at obtaining informed consent
- Subjects who have an Mini Mental State Examination (MMSE) score greater than or equal to 22 and less than or equal to 30 at Screening
- Body Mass Index (BMI) less than 35 kg/m2 at Screening
- Females must not be pregnant or lactating, and specified contraceptive precautions must be followed
- Subjects must have identified caregivers/informants
- Must have an informant or a caregiver who will provide written informed consent voluntarily and is able to spend 3 days a week with the subject (4 hours per day), and is able to support the subject during the study period by providing necessary patient information, assisting treatment compliance, and accompanying the subject to all scheduled visits (if needed) throughout the study.
- Provide voluntary written informed consent (obtaining as much as possible from subjects, but mandatory from their legal guardians).
- Willing and able to comply with all aspects of the protocol.
Exclusion Criteria
- Any neurological condition that may affect cognitive impairment
- History of transient ischemic attacks (TIA), stroke, or seizures within 12 months of Screening
- Any psychiatric diagnosis or symptoms (e.g., hallucinations, major depression, or delusions) that could interfere with study procedures in the subject
- Any medical devices contraindicated for MRI scanning (e.g., cardiac pacemaker/defibrillator, ferromagnetic metal implants, any devices other than those approved as safe for use in MRI scanners)
- Evidence of infection, tumor, stroke or other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at Screening
- Evidence of other clinically significant lesions that could indicate a dementia diagnosis other than AD on brain MRI at Screening, or other significant pathological findings on brain MRI at Screening
- A prolonged QT interval (QTcF greater than or equal to 450 ms) as demonstrated by a repeated ECG at Screening
- Any other clinically significant conditions (e.g., cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator(s) could affect the subject's safety or interfere with the study assessments
- Severe visual or hearing impairment that would prevent the subject from performing psychometric tests accurately.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BAN2401 2.5 mg/kg
Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401
|
Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
|
Experimental: BAN2401 5 mg/kg
Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401
|
Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
|
Experimental: BAN2401 10 mg/kg
Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401
|
Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
|
Placebo Comparator: Placebo
Intravenous infusions of placebo for 60 +/- 10 minutes.
|
Intravenous infusions of placebo for 60 +/- 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Up to 14 weeks
|
Safety assessment variables will include all adverse events (AEs) including serious and non-serious AEs; laboratory parameters (hematology, blood chemistry, and urinalysis); vital signs; electrocardiograms; and physical examination; as well as a risk of suicide using C-SSRS and brain MRI.
|
Up to 14 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics of BAN2401: Maximum Concentration (Cmax)
Time Frame: Up to 14 weeks
|
Cmax after single and repeated administrations based on non-compartmental analysis.
|
Up to 14 weeks
|
Pharmacokinetics of BAN2401: time attain to Cmax (tmax)
Time Frame: Up to 14 weeks
|
tmax after single and repeated administrations based on non-compartmental analysis.
|
Up to 14 weeks
|
Pharmacokinetics of BAN2401: Area under the curve (AUC)
Time Frame: Up to 14 weeks
|
AUC after single and repeated administrations based on non-compartmental analysis.
|
Up to 14 weeks
|
Pharmacokinetics of BAN2401: Drug Clearance (CL)
Time Frame: Up to 14 weeks
|
CL after single and repeated administrations based on non-compartmental analysis.
|
Up to 14 weeks
|
Pharmacokinetics of BAN2401: apparent volume of distribution at steady state (Vss)
Time Frame: Up to 14 weeks
|
Vss after single and repeated administrations based on non-compartmental analysis.
|
Up to 14 weeks
|
Investigation of the effect of repeated intravenous infusions of BAN2401 on the immunogenicity and CSF biomarkers
Time Frame: Up to 14 weeks
|
Summary statistics (mean, standard deviation, median, minimum and maximum) will be calculated for each measurement of CSF concentrations of AB1-40, AB1-42, AB1-x, total tau and p-tau and their percent changes from baseline.
|
Up to 14 weeks
|
Investigation of the effect of apolipoprotein allele4 (ApoE4) on the safety, tolerability and pharmacodynamic (PD) response of repeated intravenous infusions of BAN2401
Time Frame: Up to 14 weeks
|
Up to 14 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2013
Primary Completion (Actual)
March 1, 2015
Study Completion (Actual)
May 1, 2015
Study Registration Dates
First Submitted
January 9, 2014
First Submitted That Met QC Criteria
March 19, 2014
First Posted (Estimate)
March 24, 2014
Study Record Updates
Last Update Posted (Estimate)
June 8, 2015
Last Update Submitted That Met QC Criteria
June 4, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BAN2401-J081-104
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on BAN2401 2.5 mg/kg
-
Eisai Inc.BiogenActive, not recruitingAlzheimer's DiseaseUnited States, Canada, France, Germany, Italy, Japan, Korea, Republic of, Netherlands, Spain, Sweden, United Kingdom
-
MedImmune LLCCompletedRelapsed/Refractory Aggressive B-cell LymphomasUnited States
-
RemeGen Co., Ltd.RecruitingSystemic Lupus ErythematosusChina
-
Janssen Research & Development, LLCCompleted
-
RemeGen Co., Ltd.Completed
-
Janssen Research & Development, LLCCompletedRespiratory Syncytial VirusesTaiwan, Belgium, United Kingdom, Argentina, Panama
-
University of Texas Southwestern Medical CenterGlaxoSmithKlineRecruitingAL Amyloidosis | AmyloidosisUnited States
-
Janssen Research & Development, LLCCompletedVTE Prophylaxis With Anticoagulation After Total Knee Replacement SurgeryBelgium, Italy, Malaysia, Latvia, Spain, Turkey, Bulgaria, United States, Lithuania, Russian Federation, Ukraine, Japan, Argentina, Brazil, Canada, Poland
-
Sarah KeimOhio State University; American Diabetes Association; Ohio Department of HealthCompleted
-
Keymed Biosciences Co.LtdNot yet recruitingSystemic Lupus Erythematosus